drugset / Trial / NCT01044342

A Healthy Volunteer Study to Evaluate Reversibility of Induced Impairment of Cognition

NCT01044342

Phase 1 Completed 20 enrolled AstraZeneca
RandomizedCrossoverDouble-blindBasic science

Summary

The purpose of this study is to determine if cognitive impairment induced by scopolamine is reversed using donepezil and/or AZD1446 as compared to placebo, as assessed by electroencephalogram (EEG) measures.

Timeline

Start
2009-12
Primary completion
2010-04
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1446 Small molecule 10 mg Oral
Subject AZD1446 Small molecule 80 mg Oral
Comparator Donepezil Small molecule 5 mg Oral

Indications

No indication recorded.